董志兵,王濤
武漢工程大學化學與環境工程學院,湖北武漢 430205
一種四氫吡咯并吲哚化合物的合成及表征
董志兵,王濤
武漢工程大學化學與環境工程學院,湖北武漢 430205
四氫吡咯并吲哚骨架類生物堿由于其結構復雜性和顯著的生物活性,引起了化學家、生物學家的廣泛關注,同時,具有該核心單元(四氫吡咯并吲哚)的藥物在臨床治療中也有一定的應用價值,因此,四氫吡咯并吲哚骨架的天然產物及其衍生物的合成近年來已成為藥物化學研究領域的熱點之一.報道了一種四氫吡咯并吲哚衍生物的合成途徑:以色胺為起始原料,依次經過氨基的二碳酸二叔丁酯上保護、二氯二氰基苯醌氧、脫保護酸化、和吲哚乙酸縮合、在三氟乙酸中質子化加成,得到一種新的四氫吡咯并吲哚化合物,經過核磁共振氫譜和碳譜、高分辨質譜檢測,確定了其結構.
四氫吡咯并吲哚;縮合;色胺;吲哚乙酸
哚類生物堿(見圖1)廣泛存在于動植物體體內,該類化合物具有重要的生理活性,如嗎啡活性、抗癌活性和抗菌活性等[1-7].該類化合物的結構具有多樣性,同時,為了獲得更高的活性,化學家也努力對該類型化合物進行修飾.對該類化合物的衍生大多集中在吲哚吡咯環上,包括烷基化,芳基化或者手性控制等.大量的該類生物堿由兩個吡咯吲哚結構組合而成[8-14].該類化合物的合成具有重要研究意義,長期以來,天然或者人工合成的各類吡咯并吲哚類化合物引起了合成化學家、生物學家的廣泛關注.

圖1 具有吲哚并吡咯結構的生物堿Fig.1Alkaloids with pyrroloindoline structure
本研究以色胺為起始物,合成了一種新的吲哚吡咯化合物,合成路線見圖2.合成的關鍵步驟是最后一步:吲哚質子化環化反應,即酰胺的氮原子對吲哚2位的加成反應.該步合成中,摸索了幾種酸催化反應的條件,最終發現:在三氟乙酸做溶劑時,反應才能充分進行,并且該步反應的產率高達95%.該化合物的合成路線如下圖(圖2)所示,各步的反應條件分別為:(a)二氧六環,(BOC)2O;(b)VTHF/VH2O=9∶1,DDQ;(c)TFA;(d)DMF,NaHCO3,EDCI,HOBT;(e)TFA.

圖2 新型吲哚吡咯化合物的合成路線Fig.2Synthetic route of novel pyrroloindoline derivative
1.1 儀器與試劑
所有底物都是來自Merck或Aldrich或Alfa Aesar,所有試劑都嚴格按照標準方法處理.核磁采用Varian-400型核磁共振儀(TMS為內標,CDCl3或DMSO-d6作溶劑),液質聯用儀器采用Waters ACQUITY UPLC system液質聯用色譜儀,高分辨質譜用Finnigan MAT 95Q質譜儀測定轟擊源為EI;反應用TLC和LC-MS跟蹤;分離方法為用柱色譜分離純化,所用硅膠粒徑為0.05 mm~0.75 mm.
1.2 N-叔丁氧羰基色胺(2)的合成
取色胺(2.0 g,12.48 mmol)于100 mL三口瓶中,依次加入50 mL二氧六環,二碳酸二叔丁酯(3.0 g,13.73 mmol),三乙胺(2.0 mL,14.1 mmol),磁力攪拌3 h,取出磁子,于30℃低壓蒸除溶劑.隨后加入20 mL乙酸乙酯溶解,水洗3次,再用飽和食鹽水洗,硫酸鈉干燥,粗產物用硅膠柱層析分離純化(V石油醚∶V乙酸乙酯=2∶1)得白色固體N-叔丁氧羰基色胺∶白色固體(3.1 g),產率為95.38%.1H NMR(400 MHz,CDCl3):8.27(1H,s,1H,NH),7.62(1H,d,J=7.9Hz,ArH),7.38(1H,d,J=7.9 Hz,ArH),7.21-7.24(1H,m,ArH),7.13-7.16(1H,m,ArH),7.02(1H,s,ArH),4.67(1H,s,NH),3.48(2H,m,2-H),2.97(2H,t,J=6.7 Hz,2-H),1.47(9H,s,3-H).HRMS(ESI)m/z:calcd.For C20H17N3O2260.151 7,found 260.151 9.
1.3 化合物3的合成
將N-叔丁氧羰基色胺(2)(2.0 g,7.29 mmol)溶于20 mLVTHF/VH2O=9∶1(體積比)的溶劑中,緩慢滴加到溶于30 mL THF/H2O的DDQ(16.04 mmol,3.62 g)溶液中,反應混合物在室溫下攪拌5 h,在減壓下蒸出溶劑.反應混合物溶于50 mL乙酸乙酯溶劑中,用40 mL飽和的碳酸氫鈉溶液洗,反復洗5次,用無水硫酸鈉干燥.粗產物用硅膠柱層析分離純化(V石油醚∶V乙酸乙酯=2∶1)得白色固體3(1.50 g),產率71.26%.1H NMR(400 MHz,DMSO-d6):12.01(1H,br s,NH),8.42(1H,d,J=3.0 Hz,ArH),8.17(1H,d,J=6.6 Hz,ArH),7.48(1H,dd,J=1.8 Hz,5.6 Hz,ArH),7.25-7.17(2H,m,ArH),7.02(1H,t,J=5.8 Hz,NH),4.30(2H,d,J=5.8 Hz,2-H),1.42(9H,s,(CH3)3C).HRMS(ESI)m/z:calcd.For C20H17N3O2274.131 7,found 274.131 5.
1.4 化合物4的合成
將化合物3(1.50 g,5.47 mmol)加入到15 mL三氟乙酸中,室溫下攪拌2 h,減壓蒸出溶劑三氟乙酸(溶劑用碳酸氫鈉水溶液中和,廢液pH值呈中性至弱堿性后被收集于廢液桶),得到白色固體化合物(1.56 g),產率99.0%.1H NMR(400 MHz,DMSO-d6):12.51(1H,br s,NH),8.52(1H,d,J=3.4 Hz,ArH),8.41(3H,br s,NH2,-COOH),8.15-8.17(1H,m,ArH),7.52-7.54(1H,m,ArH),7.22-7.27(2H,m,ArH),4.36(2H,d,J=5.5 Hz,2-H).HRMS(ESI)m/z:calcd.For C12H11F3N2O3288.0722,found 288.0732.
1.5 化合物5的合成
取化合物4(1.0 g,3.47 mmol)于50 mL三口瓶中,加入DMF 25 mL,碳酸氫鈉(0.7 g,8.33 mmol),EDCI[1-(3-二甲氨基丙基)-3-乙基碳二亞胺鹽酸鹽,7 g,3.65 mmol],HOBT(1-羥基苯并三氮唑,0.5 g,3.70 mmol),吲哚乙酸(4.00 mmol)反應混合物在室溫下攪拌12 h,減壓蒸出溶劑,混合物溶于30 mL乙酸乙酯,用20 mL水洗3次,飽和食鹽水洗,硫酸鈉干燥.粗產物用硅膠柱層析分離純化(V石油醚∶V乙酸乙酯=1∶1)得到白色固體5(0.56 g),產率為49.0%.1H NMR(400 MHz,DMSO-d6):11.98(1H,s,NH),10.98(1H,s,NH),8.40(1H,d,J=3.2 Hz,NH),8.09-8.16(2H,m,ArH),7.59(1H,d,J=8.0 Hz,ArH),7.47(1H,t,J=7.7 Hz,ArH),7.35(1H,d,J=7.8 Hz,ArH),7.27(1H,m,ArH),7.20(2H,m,ArH),7.07(1H,t,J=7.6 Hz,ArH),6.97(1H,t,J=7.7 Hz,ArH),4.47(2H,t,J=3.2 Hz,2-H),3.64(2H,s,2-H).HRMS(ESI)m/z:calcd.For C20H17N3O2331.131 5,found 331.131 3.
1.6 化合物6的合成
取化合物5(100 mg,0.30 mmol)于5 mL反應瓶中,加入3 mL三氟乙酸,反應混合物在室溫下攪拌6 h,減壓下蒸出溶劑三氟乙酸(溶劑用碳酸氫鈉水溶液中和,廢液pH值呈中性至弱堿性后被收集于廢液桶),粗產物用硅膠柱層析分離純化(V石油醚∶V乙酸乙酯=1∶3)得到白色固體(95 mg),產率為95.0%.1H NMR(400 MHz,DMSO-d6):12.21(1H,s,NH),8.46(1H,s,ArH),8.14(1H,d,J=7.9 Hz,ArH),7.48(1H,d,J=7.7 Hz,ArH),7.19(2H,m,ArH),7.09(1H,d,J=7.8 Hz,ArH),6.98(1H,t,J= 7.9 Hz,ArH),6.73(1H,s,NH),6.63(1H,t,J= 7.8 Hz),6.52(1H,d,J=7.9 Hz,ArH),5.42(1H,d,J=6.4 Hz,1-H),4.80(1H,d,J=14.1 Hz,2-H),4.46(1H,d,J=14.1 Hz,2-H),4.01(1H,m,2-H),2.93(1H,m,2-H).13C NMR(400 MHz,DMSO-d6):189.05,172.67,149.20,136.54,134.08,131.28,128.19,125.14,124.38,122.98,121.13,118.24,114.03,112.36,109.28,76.56,45.56,36.29,20.73.HRMS(ESI)m/z:calcd.ForC20H17N3O2331.131 5,found 331.131 3.
以色胺為起始物,經過上保護、氧化、脫保護、縮合、質子化加成等五步反應合成出一種新的吲哚并吡咯結構的化合物[15],產物經過氫譜、碳譜、液質聯用儀分析確定了結構.具有該結構的天然產物,大多具有良好的生物活性.該類化合物的合成能為具有吲哚并吡咯結構的天然產物的合成提供一個新的選擇.另外,對化合物5的合成做了進一步分析,通過液質聯用儀監測反應表明,出現兩個副產物的峰,并且分子量和底物與兩個吲哚乙酸縮合產生副產物分子量(M=488.1)吻合,推測一部分產物生成之后,產物吲哚氮繼續與吲哚乙酸縮合,造成縮合反應的產率不高,如圖3所示.

圖3 縮合反應副產物分析Fig.3Analysis of byproducts of the condensation reaction
最終產物的合成最后一步是關鍵步驟:質子化加成反應,對該步反應條件進行了摸索,如圖4所示.反應條件的摸索采用液質聯用儀檢測,對照實驗顯示:底物在醋酸中不反應;在以N,N-二甲基甲酰胺作溶劑條件下,催化量的硫酸催化不反應;對甲苯磺酸催化不反應;催化量的三氟乙酸能獲得產物,但產率不到5%,但以三氟乙酸做溶劑的條件下,反應產率達到95%.

圖4 質子化加成反應條件摸索Fig.4Exploration of reaction conditions of protonation-addition
本文報道了一種四氫吡咯并吲哚的合成:以色胺為起始物,經過叔丁氧羰基保護、氧化、脫保護基、縮合、吡咯并吲哚環的構建等五步反應合成出新的四氫吡咯并吲哚化合物,總產率為31.32%.同時也對縮合反應的副產物和最終吡咯環的構建反應條件進行了摸索,發現以三氟乙酸做溶劑的條件下,質子化加成反應的產率很高,達到95%.本合成途徑為構建四氫吡咯并吲哚單元的化合物提供了一種合成方法,顯示出一定的應用價值.
[1]SMITH B P,TYLER M J,KANEKO T,et al.Evidence for biosynthesis of pseudophrynamine alkaloids by an Australian myobatrachid frog(Pseudophryne)and for sequestration of dietary pumiliotoxins[J].Journal of Natural Products,2002,65(4):439-447.
[2]TSUKAMOTO S,HIROTA H,KATO H,et al.Uro-chordamines A and B:larval settlement/metamorpho-sis-promoting,pteridine-containing physostigmine alka-loids from the tunicate Ciona savignyi[J].Tetrahe-dron Letters,1993,34(30):4819-4822.
[3]RUIZ-SANCHIS P,SAVINA S A,ALBERICIO F,et al.Structure,bioactivity and synthesisof natural products with hexahydropyrrolo[2,3-b]indole[J]. Chemistry-AEuropeanJournal,2011,17(5):1388-1408.
[4]HOLST P B,ANTHONI U,CHRISTPHRERSON C,et al.Marine alkaloids,15.Two alkaloids,flustramine E and debromoflustramine B,from the marine bryozoan Flustra foliacea[J].Journal of Natural Product,1994,57(7):997-1000.
[5]BROSSI A.Bioactive alkaloids.4.Results of recent investigations with colchicine and physostigmine[J]. Journal of Medicinal Chemistry,1990,33(9):2311-2319.
[6]GRIEG N H,PEI X F,SONCRANT T T,et al. Phenserine and ring C hetero-analogs:Drug candidates for the treatment of Alzheimer's disease[J].Medicinal Research Reviews,1995,15(1):3-31.
[7]SANO M,BELL K,MARDER K,et al.Safety and efficacyof oral physostigmineinthetreatment of Alzheimer disease[J].Neuropharmacol,1993,16(1):61-69.
[8]CAI Q,LIU C,LIANG X W,et al.Enantioselective construction of pyrroloindolines via chiral phosphoric acid catalyzed cascade Michael addition-cyclization of tryptamines[J].Organic Letters,2012,14(17):4588-4590.
[9]MASANORI T,KAZUHIRO H,TAKAMO I,et al. Thionium-basedone-potconstructionofhomo-/ heterodimericpyrroloindolinefromtryptamine[J]. Organic Letters,2014,16:3613-3615.
[10]REPKA L M,REISMAN S E.Recent developments in the catalytic,asymmetric construction of pyrroloin-dolines bearing all-carbon quaternary stereocenters[J]. Journal of Organic Chemistry.2013,78:12314-12320.
[11]AUSTIN J F,KIM S G,SINZ C J,et al.Enantioselective organocatalytic construction of pyrroloindolines by a cascadeaddition-cyclizationstrategy:synthesisof(-)-flustramine B[J].PNAS,2004,101(15):5482-5487.
[12]KIEFFER M E,CHUANG K V,REISMAN S E. Copper-catalyzeddiastereoselectivearylationof tryptophanderivatives:totalsynthesisof(+)-naseseazines A and B[J].Journal of the American Chemical Society,2013,135:5557-5560.
[13]LEE T B K,WONG G S K.Asymmetric alkylation of oxindoles:anapproachtothetotalsynthesisof(-)-physostigmine[J].Journal of Organic Chemistry,1991,56:872-875.
[14]STEVENA,OVERMMAN L E.Total synthesis of complexcyclotryptaminealkaloids:stereocontrolled construction of quaternary carbon stereocenters[J]. Angewandte Chemie,International Edition,2007,46:5488-5508.
[15]NICOLAOU K C,HUANGX H,LING T T,et al. Chemistry and biology of diazonamide A:first total synthesis and confirmation of the true structure[J]. Journal of the American Chemical Society,2004,126(14):12888-12896.
本文編輯:張瑞
Synthesis and Characterization of a Novel Pyrroloindoline Compound
DONG Zhibing,WANG Tao
School of Chemistry and Environmental Engineering,Wuhan Institute of Technology,Wuhan 430205,China
Alkaloids containing a pyrroloindoline unit attract extensive attention of chemists and biologists for their structural complexity and significant biological properties,and chemicals bearing pyrroloindoline skeleton were applied in clinical treatment.Thus,the synthesis of natural products bearing pyrroloindoline unit and their derivatives is a hot topic in medicinal chemistry for recent years.Hereby,we reported a synthetic method for the preparation of this novel compound which contains pyrroloindoline unit.Starting from tryptamine,then subsequently by di-tert-butyl pyrocarbonate protection of amino group,oxidation by using 2,3-dicyano-5,6-dichlorobenzoquinone,deprotection of the amino and acidification,condensation with indole-3-acetic acid,cyclization in trifluoroacetic acid,the desired product was furnished with good yield,and the structure of the target molecule is confirmed by1H NMR,13C NMR and high resolution mass spectrometry.
tetrahydropyrroloindoline;condensation;tryptamine;indole-3-acetic acid.
O621
A
10.3969/j.issn.1674-2869.2017.02.001
1674-2869(2017)02-0103-05
2017-01-03
國家自然科學基金(201302150);教育部留學回國人員基金[2012]1707;湖北省教育廳重點基金(D20131501);
武漢工程大學研究生創新基金(CX20130110);武漢工程大學校長基金(2014038)
董志兵,博士,教授.E-mail:zhibingdong80@aliyun.com
董志兵,王濤.一種四氫吡咯并吲哚化合物的合成及表征[J].武漢工程大學學報,2017,39(2):103-107.
DONG Z B,WANG T.Synthesis and characterization of a novel pyrroloindoline compound[J].Journal of Wuhan Institute of Technology,2017,39(2):103-107.